Recombinant Mouse Anti-IAV NA Antibody (CD6) (CAT#: PABL-227)

Figure 1 Therapeutic efficacy of MAbs HF5, CD6, and 1H5 against lethal pH1N1 virus challenge in mice. DBA/2 mice (n 14 or 20 per group) were infected i.n.

Jiang, L., Fantoni, G., Couzens, L., Gao, J., Plant, E., Ye, Z.,... & Wan, H. (2016). Comparative efficacy of monoclonal antibodies that bind to different epitopes of the 2009 pandemic H1N1 influenza virus neuraminidase. Journal of virology, 90(1), 117-128.

Figure 2 Lung samples collected on days 6, 8, and 10 p.c. from mice in the prophylactic study (5 mg/kg of MAb before CA/09 challenge) and the therapeutic study (three doses of 5 mg/kg MAb after CA/09 challenge) were homogenized, and the supernatant was tested in a plaque assay, in which MAb HF5 or CD6 was supplemented in the agar overlay.

Jiang, L., Fantoni, G., Couzens, L., Gao, J., Plant, E., Ye, Z.,... & Wan, H. (2016). Comparative efficacy of monoclonal antibodies that bind to different epitopes of the 2009 pandemic H1N1 influenza virus neuraminidase. Journal of virology, 90(1), 117-128.

Figure 3 CA/09 mutants with the S364N mutation (left) or the N397K mutation (middle) in the NA were examined for the sensitivities of their NAs to MAbs HF5, CD6, and 3A2 in an ELLA. (Right) Results obtained with wt CA/09 NA were included for comparison.

Jiang, L., Fantoni, G., Couzens, L., Gao, J., Plant, E., Ye, Z.,... & Wan, H. (2016). Comparative efficacy of monoclonal antibodies that bind to different epitopes of the 2009 pandemic H1N1 influenza virus neuraminidase. Journal of virology, 90(1), 117-128.

Figure 4 Prophylactic efficacy of MAbs HF5, CD6, 4E9, and 1H5 against lethal pH1N1 virus challenge in mice. DBA/2 mice (n 14 or 20 per group) were treated

Jiang, L., Fantoni, G., Couzens, L., Gao, J., Plant, E., Ye, Z.,... & Wan, H. (2016). Comparative efficacy of monoclonal antibodies that bind to different epitopes of the 2009 pandemic H1N1 influenza virus neuraminidase. Journal of virology, 90(1), 117-128.

Figure 5 Different functional properties of MAbs HF5, CD6, 4E9, and 1H5 in vitro.

(A) Inhibition of CA/09 NA activity by each MAb measured by ELLA using H6N1 CA/09 and wt CA/09 viruses. (B) CA/09 virus plaques formed in the presence of various concentrations of MAbs HF5, CD6, 4E9, and 1H5 (0.1 to 10 µg/ml) or the control MAb, 3A2 (10 µg/ml), in the overlay agar. (C) Diameters of the CA/09 virus plaques shown in panel B. Plaques from each treatment were randomly chosen, and the diameters were measured and compared to the diameter of the control. (D) Growth kinetics of CA/09 in MDCK cells in the presence of MAb HF5, CD6, 4E9, 1H5, or 3A2 (1, 5, or 10 µg/ml). Cells growing in 12-well plates were infected with CA/09 at an MOI of 0.001, and the viral titers in the supernatant at the indicated time points were measured by plaque assay. The asterisks above the green line or below the red line indicate a significant difference between the viral titers generated in the presence of the tested MAbs (CD6 or HF5) and the control MAb 3A2, asterisks between the green and red lines indicate significant differences between the viral titers generated in the presence of MAbs CD6 and HF5, and asterisks below the blue line in the right panel indicate significant differences between groups receiving 4E9 and 1H5 and the control group (which received 3A2).

Jiang, L., Fantoni, G., Couzens, L., Gao, J., Plant, E., Ye, Z.,... & Wan, H. (2016). Comparative efficacy of monoclonal antibodies that bind to different epitopes of the 2009 pandemic H1N1 influenza virus neuraminidase. Journal of virology, 90(1), 117-128.